title: Use of rituximab in Wegener's granulomatosis: comment on the article by Wong.
authors.forename: Daniel
authors.initials: D
authors.lastname: Sánchez-Cano
authors.forename: José Luis
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: Raquel
authors.initials: R
authors.lastname: Ríos-Fernández
authors.forename: Norberto
authors.initials: N
authors.lastname: Ortego-Centeno
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging; D000069283:Rituximab; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007166:Immunosuppressive Agents; D000069283:Rituximab